National Health Expenditure (NHE) projections in the USA suggest growth in spending could average 5.4% for 2019 to 2028, reaching nearly 20% of gross domestic product (GDP) by the end of the period.
The data, which were recently released by the Centers for Medicare & Medicaid Services (CMS), indicate that spending on drugs at the retail level grew by 3.2% in 2019.
The research shows that Medicare is expected to show the fastest growth in spending of all the major payers, at 7.6%, mainly as a result of high enrollment growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze